Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14387490 | 0.90 | ALOX15 (0.42) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL21810283 | 0.87 | HTT (0.49) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL1675629 | 0.87 | MAPT (0.43) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL22118191 | 0.87 | ERN1 (0.44) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL16268317 | 0.84 | MAPT (0.39) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL28074482 | 0.81 | ACHE (0.48) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL6826066 | 0.81 | PKM (0.46) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL12525248 | 0.81 | TDP1 (0.38) | TDP1KDM4EL3MBTL1POLBCTDSP1 | |
| SCHEMBL12526932 | 0.81 | L3MBTL1 (0.46) | TDP1KDM4EL3MBTL1POLBCTDSP1 | |
| SCHEMBL34475436 | 0.79 | ALDH1A1 (0.48) | PKML3MBTL1POLBMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058895-A1 | RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2016-03-03 | — | — | US | disclosed |
| US-20160058895-A1 | RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2016-03-03 | — | — | US | disclosed |
| EP-2986603-A1 | RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS | Oslo Universitetssykehus HF (NO) | 2016-02-24 | — | — | EP | disclosed |
| US-8993593-B2 | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993593-B2 | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993593-B2 | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2015-03-31 | — | — | US | disclosed |
| WO-2014184682-A9 | RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2015-01-29 | — | — | WO | disclosed |
| WO-2014184682-A1 | RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2014-11-20 | — | — | WO | disclosed |
| EP-2061465-B1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2013-04-10 | — | — | EP | disclosed |
| CN-102869250-A | 4- (N-azacycloalkyl) anilide derivatives as potassium channel modulators | VALEANT PHARMACEUTICALS INT | 2013-01-09 | — | — | CN | disclosed |
| US-20110003850-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003850-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| CN-101563085-A | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators | VERNIER JEAN MICHEL (US) | 2009-10-21 | — | — | CN | disclosed |
| EP-2061465-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008024398-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024398-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007137196-A2 | TUBULIN BINDING ANTI CANCER COMPOUNDS AND PRODRUGS THEREOF | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003850-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | KCNQ2, KCNQ1, KCNQ5 | PKM 1860/4885TDP1 2883/4885KDM4E 200/4885 |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | KCNQ2, KCNQ1, KCNQ5 | PKM 1827/4885TDP1 3025/4885KDM4E 181/4885 |
| US-20160058895-A1 | RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS | GNRHR, FSHR, GHRHR | PKM 3543/4885TDP1 1653/4885KDM4E 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.